Stockscreener 앱 받기
155.87
0.56%
0.87
시간 외 거래:
156.50
0.63
+0.40%
Guardant Health Inc 주식(GH)의 최신 뉴스
GH Maintains Rating by Guggenheim -- Price Target Raised to $190 - GuruFocus
Form 144 Guardant Health For: 16 July By Investing.com - Investing.com Canada
Guardant Health director Tariq Musa sells $18,941 in stock - Investing.com
Form 4 Guardant Health Inc For: 16 July By Investing.com - Investing.com Canada
Guardant Health director Tariq Musa sells $18,941 in stock By Investing.com - Investing.com UK
Musa Tariq plans sale of Guardant Health (NASDAQ: GH) common stock - Stock Titan
Canadian AI Microcap Cut Hospital Drug Alerts by 94%. Now It’s Entering the U.S. (TSXV: SEGN) - Benzinga
Guggenheim raises Guardant Health stock price target on Shield data - Investing.com
Guggenheim raises Guardant Health stock price target on Shield data By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
TD Cowen raises Guardant Health stock price target on FDA approval - Investing.com
How Expanded Coverage for Guardant’s Shield Test Will Impact UnitedHealth Group (UNH) Investors - simplywall.st
GH Maintained by Canaccord Genuity -- Price Target Raised to $20 - GuruFocus
Guardant Health (GH) Receives a Buy from Bank of America Securities - The Globe and Mail
BofA Securities Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $190 - Moomoo
Will Expanded Coverage of Guardant’s Shield Test Reshape UnitedHealth Group’s (UNH) Preventive Care Narrative? - Yahoo Finance
Goldman Sachs Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $165 - Moomoo
What Drove Guardant Health's Q4 2025 Performance and 2026 Outlook - Kavout | AI
Press Release: Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026 - Moomoo
Cancer Blood Screen Company’s SPAC Merger Is Delayed by Test’s Results - Barron's
Guardant Health sets July 30 call for Q2 2026 results - Stock Titan
Guardant Health (GH) Stock May Be Fully Priced As Shield Coverage Expands - simplywall.st
GH Maintained by Morgan Stanley -- Price Target Raised to $175 - GuruFocus
Guardant Health, Inc. Stock 12‑Month Price Target Raised to $161.13, Implies 3% Upside - TradingView
Morgan Stanley Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $175 - Moomoo
Guardant Health Slides as Investors Appear to Take Profits After Recent Rally - Moomoo
Citi Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $215 - Moomoo
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint - AOL.com
American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines - AOL.com
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting - AOL.com
Responsive Playbooks and the GH Inflection - Stock Traders Daily
ETFs Investing in Guardant Health, Inc. Stocks - TradingView
GH Maintained by Evercore ISI Group -- Price Target Raised to $2 - GuruFocus
Guardant Health, Inc. Stock 12‑Month Price Target Raised to $156.35, Implies 7% Downside - TradingView
Guardant Health stock hits 52-week high at $172.67 By Investing.com - Investing.com South Africa
Guardant Health stock hits 52-week high at $172.67 - Investing.com
Guardant Health: Great Execution, But At An Excessive Premium (NASDAQ:GH) - Seeking Alpha
Guardant Health Is Maintained at Buy by B of A Securities - Moomoo
BofA raises Guardant Health stock price target on FDA wins By Investing.com - Investing.com Canada
Zydus and Apollo Hospitals sign MoU to launch MCD test in India - Yahoo Finance
Guardant Health Q1 2026 slides: revenue soars 48% on Shield momentum - Investing.com
Guardant Health stock surges on colon cancer blood test news - Yahoo Finance
Guardant Health earnings on deck as cancer test volumes surge - Investing.com
GHGuardant Health Inc Latest SEC Filings - Finviz
Guardant Health (GH) Stock May Look Fully Valued Following Shield Coverage News - Yahoo Finance
Zydus, Guardant Health and Apollo Hospitals partner to launch multi-cancer blood test in India - Indian Pharma Post
Why Guardant Health (GH) Is Up 12.6% After Joining the Russell 1000 and Major Indexes – And What's Next - Yahoo Finance
Form 4 Guardant Health Inc For: 2 July By Investing.com - Investing.com Canada
Guardant Health (GH) CLO exercises RSUs as shares withheld for taxes - Stock Titan
Guardant Health | 4: Statement of changes in beneficial ownership of securities-Officer Saia John G. - Moomoo
Guardant Health (GH) CPO logs RSU vesting and $170.77 tax-withholding share transfer - Stock Titan
Guardant Health | 4: Statement of changes in beneficial ownership of securities-Officer Kalia Kumud - Moomoo
Guardant Health (GH) CIO reports RSU vesting and tax share withholding - Stock Titan
Guardant Health (GH) CCO receives 7,414 shares from RSU vesting and tax withholding - Stock Titan
Guardant Health | 4: Statement of changes in beneficial ownership of securities-Officer Chudova Darya - Moomoo
Guardant Health (GH) CTO vests RSUs; stock withheld to cover taxes - Stock Titan
Guardant Health (GH) CFO nets shares from RSU vesting and tax withholding - Stock Titan
Guardant Health | 4: Statement of changes in beneficial ownership of securities-Officer Bell Michael Brian - Moomoo
Guardant Health (GH) co-CEO exercises RSUs and pays taxes in stock - Stock Titan
Guardant Health | 4: Statement of changes in beneficial ownership of securities-Officer Talasaz AmirAli - Moomoo
Guardant Health (GH) Co-CEO reports RSU vesting and tax share withholding - Stock Titan
Guardant Health (GH) director converts 155 RSUs into common shares - Stock Titan
More than 50 million Americans remain unscreened for colon cancer New guidelines offer another option - The Cancer Letter
0.61%
1.88%
자본화:
|
볼륨(24시간):